论文部分内容阅读
目的探讨天葵胶囊治疗肥胖型多囊卵巢综合征临床疗效及机制。方法选择2014年10月—2016年12月诊断为肥胖型多囊卵巢综合征患者120例,随机分为对照组和研究组各60例。对照组患者采用二甲双胍治疗,研究组在对照组治疗基础上给予加用天葵胶囊治疗。比较两组患者治疗前后血清高敏C反应蛋白(high-sensitivity C-reactive protein,hs-CRP)、白介素-6(interleukin-6,IL-6),空腹胰岛素(fasting insulin,INS)与胰岛素抵抗指数(insulin resistance index,HOMA-IR),超声测量双侧卵巢体积,比较两组患者治疗后月经失调的临床疗效。计量资料比较采用t检验,计数资料采用χ~2检验,P<0.05为差异有统计学意义。结果与治疗前比较,治疗后两组患者血清IL-6、hs-CRP水平[(12.78±2.38)pg/ml、(10.92±2.18)mg/L与(21.67±3.43)pg/ml、(18.76±3.26)mg/L]下降,研究组下降幅度高于对照组,差异均有统计学意义(均P<0.05)。与治疗前比较,治疗后两组患者空腹胰岛素、HOMA-IR水平[(11.90±1.74)mmol/L、(2.01±0.18)与(13.56±1.54)mmol/L、(2.29±0.26)]均下降,研究组下降幅度高于对照组,差异均有统计学意义(均P<0.05)。治疗后两组患者卵巢体积均减小[(9.23±1.49)、(9.01±1.18)cm3,(11.87±1.65)、(10.29±2.26)cm3],天葵组患者治疗后卵巢体积小于对照组,差异均有统计学意义(均P<0.05)。治疗后天葵组患者临床月经失调有效率(88.33%)高于对照组(66.67%),差异有统计学意义(P<0.05)。结论天葵胶囊治疗肥胖型多囊卵巢综合征具有较好疗效,分析其原因与下调体内炎性介质反应水平有关。
Objective To investigate the clinical efficacy and mechanism of “Tian Kui Capsule” in the treatment of obese polycystic ovary syndrome. Methods One hundred and twenty patients diagnosed as obese polycystic ovary syndrome from October 2014 to December 2016 were randomly divided into control group and study group with 60 cases each. Patients in the control group were treated with metformin, and the study group was treated with the use of sunflower capsule on the basis of the control group. The levels of serum high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), fasting insulin (INS) and insulin resistance index (insulin resistance index, HOMA-IR). The ovarian volume was measured by ultrasound. The clinical efficacy of menstrual disorders after treatment was compared between the two groups. Measurement data using t test, count data using χ ~ 2 test, P <0.05 for the difference was statistically significant. Results Compared with those before treatment, the levels of IL-6 and hs-CRP in the two groups after treatment were significantly higher than those before treatment [(12.78 ± 2.38) pg / ml, (10.92 ± 2.18) mg / L vs (21.67 ± 3.43) pg / ml, ± 3.26) mg / L], the decrease of the study group was higher than that of the control group (all P <0.05). Compared with those before treatment, fasting insulin and HOMA-IR levels in both groups were significantly lower than those before treatment [(11.90 ± 1.74) mmol / L, (2.01 ± 0.18) vs (13.56 ± 1.54) mmol / L , The research group decreased more than the control group, the differences were statistically significant (P <0.05). After treatment, the ovarian volume of both groups decreased ([9.23 ± 1.49], (9.01 ± 1.18) cm3, (11.87 ± 1.65), (10.29 ± 2.26) cm3] The differences were statistically significant (all P <0.05). After treatment, the effective rate of clinical menstrual disorders (88.33%) was higher than that of the control group (66.67%), the difference was statistically significant (P <0.05). Conclusion Capsule of sunflower has a good effect in the treatment of obese patients with polycystic ovary syndrome, and its reason is related to the reduction of inflammatory mediators in vivo.